EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia
Cell Communication and Signaling · 2024
DOI: 10.1186/s12964-024-01596-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Communication and Signaling, 2024. Verfasst von Zhijie Hou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dali…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Trans-Activators. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Youth Talent Cultivation Fund Project of Dalian Medical University, the Basic Research project of the Educational Department of Liaoning Province, the Central Guidance on Local Science and Technology Development Fund of Liaoning Province.
Abstract (Originalsprache)
The EP300-ZNF384 fusion gene is an oncogenic driver in B-cell acute lymphoblastic leukemia (B-ALL). In the present study, we demonstrated that EP300-ZNF384 substantially induces the transcription of IL3RA and the expression of IL3Rα (CD123) on B-ALL cell membranes. Interleukin 3 (IL-3) supplementation promotes the proliferation of EP300-ZNF348 -positive B-ALL cells by activating STAT5. Conditional knockdown of IL3RA in EP300-ZF384 -positive cells inhibited the proliferation in vitro, and induced a significant increase in overall survival of mice, which is attributed to impaired propagation ability of leukemia cells. Mechanistically, the EP300-ZNF384 fusion protein transactivates the promoter activity of IL3RA by binding to an A-rich sequence localized at -222/-234 of IL3RA . Furthermore, forced EP300-ZNF384 expression induces the expression of IL3Rα on cell membranes and the secretion of IL-3 in CD19-positive B precursor cells derived from healthy individuals. Doxorubicin displayed a selective killing of EP300-ZNF384- positive B-ALL cells in vitro and in vivo. Collectively, we identify IL3RA as a direct downstream target of EP300-ZNF384, suggesting CD123 is a potent biomarker for EP300-ZNF384 -driven B-ALL. Targeting CD123 may be a novel therapeutic approach to EP300-ZNF384 -positive patients, alternative or, more likely, complementary to standard chemotherapy regimen in clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dalian, 116027, China. houzhijie_818@126.com.
- Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Dalian Key Laboratory of hematology, Diamond Bay institute of hematology, Blood Stem Cell Transplantation Institute, the Sec…
- Department of Pediatric, Pediatric Oncology and Hematology Center, the Second Hospital of Dalian Medical University, Dalian, 116027, China. houzhijie_818@126.com.
- Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, 116044, China. houzhijie_818@126.com.
- Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dalian, 116027, China.
- Department of Pediatric, Pediatric Oncology and Hematology Center, the Second Hospital of Dalian Medical University, Dalian, 116027, China.
Förderung
- the Youth Talent Cultivation Fund Project of Dalian Medical University
- the Basic Research project of the Educational Department of Liaoning Province
- the Central Guidance on Local Science and Technology Development Fund of Liaoning Province
- the Science and Technology Innovation Leading Talent Program of Liaoning Province
- the Basic Research on the Application of Dalian Innovation Fund
- the Key R & D projects in Liaoning Province
- the Key Project of the Educational Department of Liaoning Province
Zitieren
APA
Hou, Z., Ren, Y., Zhang, X., Huang, D., Yan, F., Sun, W., Zhang, W., Zhang, Q., Fu, X., Lang, Z., Chu, C., Zou, B., Gao, B., Jin, B., Kang, Z., Liu, Q., & Yan, J. (2024). EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia. Cell Communication and Signaling. https://doi.org/10.1186/s12964-024-01596-9
Vancouver
Hou Z, Ren Y, Zhang X, Huang D, Yan F, Sun W, et al. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia. Cell Communication and Signaling. 2024. doi:10.1186/s12964-024-01596-9
BibTeX
@article{Hou2024,
author = {Hou, Zhijie and Ren, Yifei and Zhang, Xuehong and Huang, Dan and Yan, Fanzhi and Sun, Wentao and Zhang, Wenjuan and Zhang, Qingqing and Fu, Xihui and Lang, Zhenghui and Chu, Chenyang and Zou, Boyang and Gao, Beibei and Jin, Bilian and Kang, Zhijie and Liu, Quentin and Yan, Jinsong},
title = {EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia},
journal = {Cell Communication and Signaling},
year = {2024},
doi = {10.1186/s12964-024-01596-9}
}
EUVIMED